Abstract
Sn protoporphyrin (SnPP) and Sn mesoporphyrin (SnMP), potent inhibitors of heme oxygenase (HO), significantly suppress bilirubin production, lower serum and biliary bilirubin levels and increase biliary heme output in animals and man. In this study, 20 healthy volunteers, 7 patients with primary biliary cirrhosis and 4 patients with idiopathic hemochromatosis were treated with SnPP and 4 healthy volunteers with SnMP. In all cases, serum ferritin levels increased substantially but transiently after administration of these HO inhibitors. Values returned to baseline within a few days. Infusion of hematin in 4 healthy volunteers did not significantly affect ferritin levels. No increases occurred in 7 other acute-phase reactants. The observation that these HO inhibitors transiently increase serum ferritin levels implies a link between ferritin, iron metabolism and HO activity which may be usefully explored in disorders of iron metabolism.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 51-56 |
| Number of pages | 6 |
| Journal | Pharmacology |
| Volume | 59 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 1999 |
| Externally published | Yes |
Fingerprint
Keywords
- Bilirubin
- Ferritin
- Heme
- Heme oxygenase inhibitors
- Iron metabolism
ASJC Scopus subject areas
- Pharmacology
Cite this
Heme oxygenase inhibitors transiently increase serum ferritin concentrations without altering other acute-phase reactants in man. / Berglund, Lars; Galbraith, Richard A.; Emtestam, Lennart; Drummond, George S.; Angelin, Bo; Kappas, Attallah.
In: Pharmacology, Vol. 59, No. 1, 07.1999, p. 51-56.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Heme oxygenase inhibitors transiently increase serum ferritin concentrations without altering other acute-phase reactants in man
AU - Berglund, Lars
AU - Galbraith, Richard A.
AU - Emtestam, Lennart
AU - Drummond, George S.
AU - Angelin, Bo
AU - Kappas, Attallah
PY - 1999/7
Y1 - 1999/7
N2 - Sn protoporphyrin (SnPP) and Sn mesoporphyrin (SnMP), potent inhibitors of heme oxygenase (HO), significantly suppress bilirubin production, lower serum and biliary bilirubin levels and increase biliary heme output in animals and man. In this study, 20 healthy volunteers, 7 patients with primary biliary cirrhosis and 4 patients with idiopathic hemochromatosis were treated with SnPP and 4 healthy volunteers with SnMP. In all cases, serum ferritin levels increased substantially but transiently after administration of these HO inhibitors. Values returned to baseline within a few days. Infusion of hematin in 4 healthy volunteers did not significantly affect ferritin levels. No increases occurred in 7 other acute-phase reactants. The observation that these HO inhibitors transiently increase serum ferritin levels implies a link between ferritin, iron metabolism and HO activity which may be usefully explored in disorders of iron metabolism.
AB - Sn protoporphyrin (SnPP) and Sn mesoporphyrin (SnMP), potent inhibitors of heme oxygenase (HO), significantly suppress bilirubin production, lower serum and biliary bilirubin levels and increase biliary heme output in animals and man. In this study, 20 healthy volunteers, 7 patients with primary biliary cirrhosis and 4 patients with idiopathic hemochromatosis were treated with SnPP and 4 healthy volunteers with SnMP. In all cases, serum ferritin levels increased substantially but transiently after administration of these HO inhibitors. Values returned to baseline within a few days. Infusion of hematin in 4 healthy volunteers did not significantly affect ferritin levels. No increases occurred in 7 other acute-phase reactants. The observation that these HO inhibitors transiently increase serum ferritin levels implies a link between ferritin, iron metabolism and HO activity which may be usefully explored in disorders of iron metabolism.
KW - Bilirubin
KW - Ferritin
KW - Heme
KW - Heme oxygenase inhibitors
KW - Iron metabolism
UR - http://www.scopus.com/inward/record.url?scp=0033044953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033044953&partnerID=8YFLogxK
U2 - 10.1159/000028305
DO - 10.1159/000028305
M3 - Article
C2 - 10352426
AN - SCOPUS:0033044953
VL - 59
SP - 51
EP - 56
JO - Pharmacology
JF - Pharmacology
SN - 0031-7012
IS - 1
ER -